Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (171-180 of 271) with videos related to

Pageof 28
Sort By:
Journal of the International Association of Providers of AIDS Care|November 22, 2019
Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIVJenna Lynn Yager, Ryan Patrick Coyle, Stacey Summer Coleman, et al.
AIDS and Behavior|August 19, 2022
Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with MenSusan P Buchbinder, Aaron J Siegler, Kenneth Coleman, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2025
Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIVVincent A Mainella, Brian Branchford, Travis Nemkov, et al.
The Lancet. HIV|March 4, 2021
Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trialJessica E Haberer, Elizabeth A Bukusi, Nelly R Mugo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 17, 2019
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence TestingMatthew A Spinelli, David V Glidden, Peter L Anderson, et al.
Medrxiv : the Preprint Server for Health Sciences|April 3, 2026
An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted GerotherapeuticsPeter L Anderson, Alina Ps Pang, Ryan P Coyle, et al.
Antimicrobial Agents and Chemotherapy|July 30, 2024
Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfectionJihyun Bae, Marwa Tantawy, Yan Gong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 2, 2020
Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes MellitusSarah C Mann, Mary Morrow, Ryan P Coyle, et al.
AIDS (London, England)|July 13, 2017
Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis usersLuxi Lal, Jennifer Audsley, Dean A Murphy, et al.
The Lancet. HIV|December 4, 2018
Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case reportStephanie E Cohen, Darpun Sachdev, Sulggi A Lee, et al.
Pageof 28

Showing results (171-180 of 271) with videos related to

Sort By:
Pageof 28
Journal of the International Association of Providers of AIDS Care|November 22, 2019
Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIVJenna Lynn Yager, Ryan Patrick Coyle, Stacey Summer Coleman, et al.
AIDS and Behavior|August 19, 2022
Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with MenSusan P Buchbinder, Aaron J Siegler, Kenneth Coleman, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2025
Cellular pharmacology of tenofovir alafenamide and emtricitabine in neutrophils and platelets in people with and without HIVVincent A Mainella, Brian Branchford, Travis Nemkov, et al.
The Lancet. HIV|March 4, 2021
Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trialJessica E Haberer, Elizabeth A Bukusi, Nelly R Mugo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 17, 2019
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence TestingMatthew A Spinelli, David V Glidden, Peter L Anderson, et al.
Medrxiv : the Preprint Server for Health Sciences|April 3, 2026
An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted GerotherapeuticsPeter L Anderson, Alina Ps Pang, Ryan P Coyle, et al.
Antimicrobial Agents and Chemotherapy|July 30, 2024
Pharmacogenetic determinants of tenofovir diphosphate and lamivudine triphosphate concentrations in people with HIV/HBV coinfectionJihyun Bae, Marwa Tantawy, Yan Gong, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 2, 2020
Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes MellitusSarah C Mann, Mary Morrow, Ryan P Coyle, et al.
AIDS (London, England)|July 13, 2017
Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis usersLuxi Lal, Jennifer Audsley, Dean A Murphy, et al.
The Lancet. HIV|December 4, 2018
Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case reportStephanie E Cohen, Darpun Sachdev, Sulggi A Lee, et al.
Pageof 28